Osteoporos Int. 2016 Oct 31. [Epub ahead of print] DOI: 10.1007/s00198-016-3769-2 PMID: 27796445 [PubMed – as supplied by publisher]
In this review, the authors present the best evidence available regarding bone loss in RA patients. The more recent knowledge of the cytokines’ interplay in the inflamed synovial membrane and its close relation to osteoclast development and activation demonstrated that the persistence of inflammation enhanced bone turnover, leading to bone erosions and systemic bone loss. Early and “aggressive” treatments were reported to be more effective in rapidly achieving a low level of inflammation and halting the progressive loss of bone. Although several studies reported favorable actions of biologic therapies on bone protection, there are still unmet needs for studies regarding their actions on the risk of bone fractures in RA patients. They will be developed in the near future or they are probably underway at this time.
Autor: Zerbini CA, Clark P, Mendez-Sanchez L, Pereira RM, Messina OD, Uña CR, Adachi JD, Lems WF, Cooper C, Lane NE; IOF Chronic Inflammation and Bone Structure (CIBS) Working Group.